Can Circulating Tumor DNA Inform Breast Cancer Treatment?

The phase 3 INAVO120 trial reported statistically significant OS results in patients with PIK3CA-mutant, locally advanced or metastatic breast cancer.

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

Data show a trend towards a reduced risk of death with fulvestrant vs anastrozole among patients with nonvisceral disease in the phase 3 FALCON trial.

A study evaluating disparities in breast reconstructive surgery sought to assess the impact of culture, race, and ethnicity in minority groups.

Data from the TROPION-Breast01 trial support the FDA approval of datopotamab deruxtecan for those with metastatic HR–positive, HER2-negative breast cancer.

Data support the IGG signature, especially its key gene subset, as a potential marker of sustained antitumor activity in breast cancer.